Cargando…

A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males

PURPOSE: The purpose of this study was to characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of an oral inositol-stabilized arginine silicate dietary supplement. SUBJECTS AND METHODS: Ten healthy males, 26.7±5.4 years, took three 500 mg arginine silicate capsules (active product) for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalman, Douglas S, Feldman, Samantha, Samson, Adam, Krieger, Diane R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603712/
https://www.ncbi.nlm.nih.gov/pubmed/26504409
http://dx.doi.org/10.2147/CPAA.S84206
_version_ 1782394942315823104
author Kalman, Douglas S
Feldman, Samantha
Samson, Adam
Krieger, Diane R
author_facet Kalman, Douglas S
Feldman, Samantha
Samson, Adam
Krieger, Diane R
author_sort Kalman, Douglas S
collection PubMed
description PURPOSE: The purpose of this study was to characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of an oral inositol-stabilized arginine silicate dietary supplement. SUBJECTS AND METHODS: Ten healthy males, 26.7±5.4 years, took three 500 mg arginine silicate capsules (active product) for 14 days. The subjects attended test visits on Days 1 and 14. Fasting blood and saliva collections were performed predose and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours postdose for plasma arginine, serum silicon, and salivary nitric oxide (NO) + nitrite. RESULTS: Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C(Max)) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t(Max)) 1.13±0.52 hours, and time required to reach half its original concentration (t(1/2)) 15.93±9.55 hours and for silicon were C(Max) 2.99±0.63 μg/mL, t(Max) 2.44±2.05 hours, and t(1/2) 34.56±16.56 hours. After Day 1 dose, arginine levels increased at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, and 5 hours (P<0.01) and silicon levels increased at 1 hour and 1.5 hours (P<0.05). After Day 14 dose, arginine levels increased at 0.5 hours, 1 hour, and 1.5 hours (P<0.05) and silicon levels increased at 1 hour, 1.5 hours, 2 hours, and 3 hours (P<0.01). After 14 days of use, baseline arginine trended toward being higher than baseline Day 1 (P=0.0645), and 4-hour postdose plasma arginine was significantly higher (P=0.0488) at Day 14 than Day 1. Although not a significant difference, NO, as measured as salivary nitrate, increased in four subjects and stayed the same in six subjects at 0.5 hours after the first dose (P=0.125). After 14 days of use, baseline NO levels increased in six subjects and stayed the same in four subjects; this shift was significant (P=0.031). CONCLUSION: The arginine silicate dietary supplement increases blood levels of arginine after a single dose within 30 minutes and blood levels of silicon for up to 1.5 hours. Blood levels of arginine, silicon, and NO (salivary nitrite) were elevated consistently after 14 days of use. The observed increase in baseline salivary nitrite is supporting information that there was some improvement in NO production. Further study on the effect of this supplement on NO production and the resulting physiological effect is warranted. Within the specific protocol of this study, the product was found to be safe.
format Online
Article
Text
id pubmed-4603712
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46037122015-10-26 A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males Kalman, Douglas S Feldman, Samantha Samson, Adam Krieger, Diane R Clin Pharmacol Original Research PURPOSE: The purpose of this study was to characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of an oral inositol-stabilized arginine silicate dietary supplement. SUBJECTS AND METHODS: Ten healthy males, 26.7±5.4 years, took three 500 mg arginine silicate capsules (active product) for 14 days. The subjects attended test visits on Days 1 and 14. Fasting blood and saliva collections were performed predose and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours postdose for plasma arginine, serum silicon, and salivary nitric oxide (NO) + nitrite. RESULTS: Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C(Max)) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t(Max)) 1.13±0.52 hours, and time required to reach half its original concentration (t(1/2)) 15.93±9.55 hours and for silicon were C(Max) 2.99±0.63 μg/mL, t(Max) 2.44±2.05 hours, and t(1/2) 34.56±16.56 hours. After Day 1 dose, arginine levels increased at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, and 5 hours (P<0.01) and silicon levels increased at 1 hour and 1.5 hours (P<0.05). After Day 14 dose, arginine levels increased at 0.5 hours, 1 hour, and 1.5 hours (P<0.05) and silicon levels increased at 1 hour, 1.5 hours, 2 hours, and 3 hours (P<0.01). After 14 days of use, baseline arginine trended toward being higher than baseline Day 1 (P=0.0645), and 4-hour postdose plasma arginine was significantly higher (P=0.0488) at Day 14 than Day 1. Although not a significant difference, NO, as measured as salivary nitrate, increased in four subjects and stayed the same in six subjects at 0.5 hours after the first dose (P=0.125). After 14 days of use, baseline NO levels increased in six subjects and stayed the same in four subjects; this shift was significant (P=0.031). CONCLUSION: The arginine silicate dietary supplement increases blood levels of arginine after a single dose within 30 minutes and blood levels of silicon for up to 1.5 hours. Blood levels of arginine, silicon, and NO (salivary nitrite) were elevated consistently after 14 days of use. The observed increase in baseline salivary nitrite is supporting information that there was some improvement in NO production. Further study on the effect of this supplement on NO production and the resulting physiological effect is warranted. Within the specific protocol of this study, the product was found to be safe. Dove Medical Press 2015-10-07 /pmc/articles/PMC4603712/ /pubmed/26504409 http://dx.doi.org/10.2147/CPAA.S84206 Text en © 2015 Kalman et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kalman, Douglas S
Feldman, Samantha
Samson, Adam
Krieger, Diane R
A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title_full A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title_fullStr A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title_full_unstemmed A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title_short A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
title_sort clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603712/
https://www.ncbi.nlm.nih.gov/pubmed/26504409
http://dx.doi.org/10.2147/CPAA.S84206
work_keys_str_mv AT kalmandouglass aclinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT feldmansamantha aclinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT samsonadam aclinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT kriegerdianer aclinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT kalmandouglass clinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT feldmansamantha clinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT samsonadam clinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales
AT kriegerdianer clinicalevaluationtodeterminethesafetypharmacokineticsandpharmacodynamicsofaninositolstabilizedargininesilicatedietarysupplementinhealthyadultmales